甘精胰島素市場:各類型(甘精胰島素)，各地區(北美，歐洲，亞太地區，中東·非洲，南美)-規模，佔有率，展望，機會分析，2022年～2028年

Insulin Glargine Market, By Type (Insulin Glargine) and By Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

出版日期: 2022年09月20日 | 出版商:

Coherent Market Insights | 英文 167 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

市場力學。

糖尿病患病率的增加、老年人口的增加、臨床試驗數量的增加、研發的增加以及公眾意識的提高是預計將有助於全球甘精胰島素市場增長的一些主要因素。

本調查的主要特徵

本報告提供以2021年為基準年的預測期間（2022-2030 年）之全球甘精胰島素市場的市場規模和復合年增長率（CAGR %）相關的詳細分析。
並闡明不同部門市場的潛在收入機會，說明該市場具有魅力的投資主張矩陣。
同時並提供市場推動因素和限制、機會、新產品發布或批准、市場趨勢、區域前景和主要參與者採用的競爭戰略等重要考察。
並基於企業亮點，各類型投資組合、主要焦點、財務業績和市場策略等參數，介紹全球甘精胰島素市場的主要參與者之企業簡介。
藉由該報告提供的洞察，將能幫助營銷人員和公司高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。
全球甘精胰島素市場報告配合該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
利益相關者可以透過全球甘精胰島素市場用於分析的各種戰略矩陣來幫助他們更容易做下決策。

Insulin glargine is a long-acting, synthetic version of human insulin. It belongs to a drug class called long-acting insulins. It is a form of medical insulin used to manage type I and type II diabetes. Like other types of insulin, insulin glargine is used to keep blood sugar level close to normal. It works by replacing the insulin that is produced by the body and by helping move sugar from the blood into other body tissues where it is used for the energy. Insulin glargine is FDA approved to treat adults and children with type 1 diabetes and adults with type 2 diabetes. Thus, there is an increase in demand for insulin glargine worldwide.

Market Dynamics:

Increase in prevalence of diabetes, growing geriatric population, increase in number of clinical trials, increase in research and development, and increase in awareness among people are some major factors expected to aid in the growth of the global insulin glargine market.

In January 2022, FDA announced its approval of Rezvoglar (insulin glargine-aglr), a new long-acting basal insulin, for adults and children with type 1 diabetes and adults with type 2 diabetes. Rezvoglar was approved as a biosimilar to Sanofi's Lantus (insulin glargine).

In December 2021, FDA approved a second insulin glargine biosimilar, an Eli Lilly product called Rezvoglar, which references Lantus.

In June 2020, Biocon and Mylan got the U.S. food and drug administration nod to launch for its insulin glargine injection in vial and pre-filled pen presentations, to control high blood sugar in adults with type 2 diabetes and adult and pediatric patients with type 1 diabetes.

Key features of the study:

This report provides in-depth analysis of the global insulin glargine market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global insulin glargine market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Julphar, Biocon, Eli Lilly, Sanofi Aventis, and Novo Nordisk AS, among others.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global insulin glargine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global insulin glargine market.

Detailed Segmentation:

Global Insulin Glargine Market By Type:
- Insulin Glargine
Global Insulin Glargine Market By Geography:
- North America
- Europe
- Asia-Pacific
- Middle East and Africa
- South America
Company Profiles:
- Julphar
- Biocon
- Eli Lilly
- Sanofi Aventis
- Novo Nordisk AS

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
Middle East and Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
Rest of World
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)

7. Competitive Landscape

Julphar
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Biocon
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Eli Lilly
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi Aventis
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novo Nordisk AS
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Analyst Views